MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Copper"

  • 2025 International Congress

    Correlation of 7T MRI Susceptibility and Retinal Nerve Fiber Thickness with Neurological Severity in Wilson’s Disease

    I. Brum, I. Prates, J. Cordeiro, F. Otsuka, R. Guidi, P. Barbosa, R. Cury, M. Otaduy, L. Lucato, E. Barbosa, J. Parmera (Sao Paulo, Brazil)

    Objective: To evaluate susceptibility changes in the lentiform nucleus using 7T MRI and peripapillary retinal nerve fiber layer (p-RNFL) thickness using Optical Coherence Tomography (OCT)…
  • 2024 International Congress

    A Case of Concurrent Wilson Disease and Parkinson Disease

    C. Tapia, M. Davis, M. Penon-Portmann, S. Hahn, E. Rezvanian (Seattle, USA)

    Objective: to present a case of concurrent Wilson disease and Parkinson disease. Background: Wilson disease (WD) is a rare autosomal recessive disease that typically manifests…
  • 2024 International Congress

    Wilson Disease Presenting as Rapidly Progressive Dementia

    V. Chang, E. Brown (San Francisco, USA)

    Objective: To describe an atypical presentation of Wilson Disease. Background: Wilson Disease is a rare autosomal recessive disorder that causes copper accumulation in the brain…
  • 2024 International Congress

    A Curious Case of Copper de-Compensation

    D. Tang, CH. Tan, SF. Woo, D. Soon, J. Tan (Singapore, Singapore)

    Objective: To describe the investigation and management of a patient with Wilson’s disease who experienced late-onset neurological deterioration despite continued treatment. Background: Wilson’s disease is…
  • 2024 International Congress

    Increased Brain-Age Gap Estimate (BrainAGE) in Neurological Wilson Disease

    A. Hausmann, J. Caspers, S. Kannenberg, S. More, K. Patil, A. Schnitzler, C. Rubbert, C. Hartmann (Duesseldorf, Germany)

    Objective: To assess grey matter (GM) volume derived brain-aging in Wilson Disease (WD) using a previously proposed machine learning (ML) algorithm. Background: GM atrophy is…
  • 2024 International Congress

    Laboratory changes of the liver function in the patients with Wilson’s disease

    I. Voloshyn-Haponov, A. Teslenko, L. Cherkashyna, O. Korzh (Kharkiv, Ukraine)

    Objective: Wilson's disease (WD) is a chronic progressive neurodegenerative disease with a genetically determined disorder of copper metabolism due to mutations in the ATP7B gene,…
  • 2024 International Congress

    Wilson’s Disease : A Senegalese Series of Seven Patients Followed at Pikine National Hospital Centre (Dakar-Senegal)

    M. Fall, A. Diop, J. Kahwagi (Dakar, Senegal)

    Objective: The aim of this study is to describe the epidemiological, diagnostic, therapeutic and evolutionary characteristics of Wilson's disease and to highlight the diagnostic and…
  • 2024 International Congress

    Transition from Zinc Salts to Trientine Tetrahydrochloride in Wilson Disease: Clinical and Biochemical Effects over Two Years – the ZICUP study

    A. Poujois, MA. Obadia, N. Oussedik-Djebrani, E. Couchonnal-Bedoya, F. Ory-Magne, D. Debray (France, France)

    Objective: To assess the clinical and biochemical effects of transitioning from zinc salts (ZS) to trientine tetrahydrochloride (TETA4HCL) in Wilson disease (WD) patients over a…
  • 2023 International Congress

    Wilson disease: a single-center study from Tunisia

    R. Zouari, R. Amouri, I. Ben Kraiem, MZ. Saeid, F. Nabli, S. Ben Sassi (Tunis, Tunisia)

    Objective: We aimed to describe different clinical and radiological presentations of WD and insist on the necessity of early diagnosis to ensure therapeutic efficiency. Background:…
  • 2023 International Congress

    Minimum clinically important difference (MCID) on the Unified Wilson Disease Rating Scale (UWDRS) Part III: results from the Phase 3 FoCus Trial

    T. Litwin, A. Czlonkowska, P. Hedera, J. Bronstein, M. Lorincz, M. Møller, G. Wegmann, G. Carron, A. Messali, A. Poujois (Warsaw, Poland)

    Objective: Minimum clinically important differences (MCID) on the Unified Wilson Disease Rating Scale (UWDRS) Part III were estimated using data from a phase III trial…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley